Stanislav Byshenko
Internal Medicine · Sharon, PANPI 1891088415
Payments from drug & device makers
Across 292 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$906
- GSK$797
- Lilly USA, LLC$767
- Novo Nordisk$687
- Pfizer$500
- plus $2K from 20 others
What the payments were for
- Food & beverage$7,029100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $1,200 |
| Amgen | 61 | $906 |
| GSK | 38 | $797 |
| Lilly USA, LLC | 34 | $767 |
| Novo Nordisk | 25 | $687 |
| Pfizer | 33 | $500 |
| Bayer | 11 | $378 |
| Esperion Therapeutics, Inc. | 3 | $262 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $206 |
| Biohaven Pharmaceuticals, Inc. | 6 | $192 |
| AbbVie | 4 | $180 |
| E.r. Squibb & Sons, L.L.C. | 2 | $167 |
| Johnson & Johnson | 9 | $153 |
| Boston Scientific | 1 | $143 |
| Genentech USA, Inc. | 1 | $100 |
| Boehringer Ingelheim | 2 | $90 |
| Sunovion Pharmaceuticals Inc. | 3 | $71 |
| Lundbeck LLC | 2 | $46 |
| Novartis | 3 | $42 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Exact Sciences | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,037 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 103 | $99,785 |
| MounjaroTirzepatide | 61 | $64,529 |
| JardianceEmpagliflozin | 56 | $58,427 |
| OzempicSemaglutide | 44 | $51,212 |
| EliquisApixaban | 58 | $50,028 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $49,594 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $26,149 |
| Repatha SureclickEvolocumab | 40 | $21,644 |
| FarxigaDapagliflozin Propanediol | 15 | $20,366 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $17,212 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $16,311 |
| Repatha SyringeEvolocumab | 24 | $13,303 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 98 | $11,286 |
| XareltoRivaroxaban | 15 | $10,652 |
| NexletolBempedoic Acid | 24 | $9,626 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $767 | $164,314164 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $90 | $64,47769 claims |
| Novo NordiskOzempic | $687 | $51,21244 claims |
| PfizerEliquis | $500 | $50,02858 claims |
| GSKTrelegy Ellipta | $797 | $49,59466 claims |
| AstraZenecaFarxiga | $1,200 | $20,36615 claims |
| Johnson & JohnsonXarelto | $153 | $10,65215 claims |
| Esperion Therapeutics, Inc.Nexletol | $262 | $9,62624 claims |
| AbbVieSynthroid | $180 | $1,17714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Sharon
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.